Table 4 Tumor response and associated median survival (n = 39)
From: Thymostimulin in advanced hepatocellular carcinoma: A phase II trial
No. of patients | Median survival (range) | 95% CI | |
|---|---|---|---|
Complete response (CR) | 2 (5%) | > 51 months* | |
with concomitant treatment (RFTA) | 1 | (> 51 months*) | |
without concomitant treatment | 1 | (> 51 months*) | |
Partial response (PR) | 5 (13%) | 18 months | 14–22 |
with concomitant treatment (TACE/RFTA) | 2 | (range 15.7–55.4) | |
without concomitant treatment | 3 | (range 3.9–24.8) | |
Stable disease (SD) | 24 (61%) | 14 months | 11–17 |
Progressive disease (PD) | 8 (21%) | 4 months | 0 – 8 |
Objective response (CR+PR) | 7 (18%) | 25 months | 20–29 |
Tumor control rate (CR+PR+SD) | 31 (79%) | 16 months | 11–20 |